Why DRTS Stock slipped -1.28% Today — RQD Quant Desk Flash

Per the Roarable RQD rating, DRTS scores 39 out of 100, earning a D- grade and the verdict label "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:

• Fundamental Cash Engine: 6 / 20. Per the RQD rating, ROIC is -35% and FCF yield is -2.68%. This is the weakest pillar and signals that the business is currently consuming cash rather than generating it. For a prospective investor, the upside case depends on a future cash-generating inflection that the source data does not show.
• Whale 13F Flow: 10 / 20. The RQD rating describes institutional accumulation and options positioning, but the holders section in the source data is empty, so the specific flows cannot be verified here. Institutional interest may support the price in the near term, but it is not independently confirmed in this dossier.
• Insider Conviction: 3 / 20. The lowest-scoring pillar after Cash Engine, reflecting SEC Form 4 and Congressional PTR cluster flow per the RQD rating. Weak insider conviction is a caution signal, since insiders typically have the deepest information about the company's trajectory.
• Macro Regime Fit: 10 / 20. Per the RQD rating, beta is 1.0 and the score reflects sector sensitivity. A beta of 1.0 means the stock is expected to move broadly in line with the market, so it offers no defensive cushion in a downturn.
• Forensic Balance Sheet: 10 / 20. Per the RQD rating, Altman Z is 2.5, Piotroski F is 2/9, and Debt/Equity is 0.5. The Piotroski score is weak and the Altman figure sits in an intermediate zone, so balance sheet resilience is moderate at best.

Taken together, the valuation tradeoff is stark: the market capitalization of $1.22B is being supported by a business that reports no revenue and deep operating losses. A prospective investor is therefore pricing in future commercial success, and the RQD rating indicates that the current evidence for that success is limited.

Alpha Tau Medical Ltd. (DRTS) is a NASDAQ-listed issuer in the Health Care sector, operating within the Medical/Dental Instruments industry. Per the profile, the company has a market capitalization of $1.2B. The source data does not describe its specific products, customers, or revenue model. Reported revenue is $0.0M in each period shown, so the source data does not establish a commercial revenue stream.

Per the SEC financials, operating losses widened from $-35.7M in FY 2023 to $-42.3M in FY 2025, and free cash flow outflows grew from $-18.0M to $-32.8M over the same span. Gross, operating, and net margins are each reported as 0% per the market data, consistent with zero revenue. ROIC is -35% per the market data. Per the RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9. Cash declined from $13.7M in FY 2024 to $12.2M in FY 2025, and debt is reported as N/A in every period, so the balance sheet posture cannot be fully characterized from the source data.

Per the recent news and catalysts section, the most prominent items concern clinical and regulatory expansion:

• An item reports an expanded brain cancer trial, and a separate item covers an expanded glioblastoma trial and its potential impact on the stock.
• An item reports that the FDA allows a larger cancer trial at three U.S. centers.
• An item reports a memorandum of understanding with Samsung Medical Center for a pancreatic cancer trial in Korea.
• An item reports H.C. Wainwright reiterating its rating on the trial expansion.

All six items are tagged with a YELLOW light and MARKET WIRE impact label. Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals. The catalysts therefore represent clinical and regulatory milestones rather than quantified commercial signals. Key watch items are the progress and outcomes of the expanded trials, and whether the clinical expansion converts to revenue, which the financials do not yet show.

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, there are no butterfly links, and no proprietary signals are present. Upstream suppliers, downstream customers, and sector correlations therefore cannot be mapped from the source data. The only sector context available is the classification of Health Care / Medical/Dental Instruments. A prospective investor should note that 2nd-order ripple effects, such as dependence on trial sites, partners, or regulators, are not documented in the supplied data.

• What specific product or technology does Alpha Tau Medical commercialize, and what is its expected path to revenue given zero reported revenue in FY 2023 through FY 2025?
• What are the terms and milestones of the Samsung Medical Center memorandum of understanding, and how material are the expanded trials to near-term cash needs?
• How will the company fund operating losses of $-42.3M in FY 2025 given cash of $12.2M, and what is its debt position, which is reported as N/A?
• What drove the stock's 52-week range of $3.43 to $15.79, and what institutional or insider activity accompanied those moves?
• Why are the P/E, EPS, and EV/EBITDA metrics unavailable, and what would a valuation framework look like for a pre-revenue company at this market capitalization?